Treating Anemia in MDS

A pocket guide on active treatments for anemia in patients with MDS

Goals of Treatment

Many patients with MDS become transfusion-dependent, resulting in complications. Active treatments can be used to help manage anemia associated with MDS. The primary goals of active treatment for LR-MDS are to increase patient quality of life by improving cytopenias and decreasing transfusion burden.[1]

Active Treatments

Official recommendations describing the use of active treatments for MDS continue to evolve. **Please review the latest NCCN Guidelines® for more information. Scan QR code here.**

	Mechanism of action	Role in MDS
Erythroid Maturation Agents (EMAs)[2,3]	Fusion proteins that inhibit the activity of TGF-β ligands, allowing for erythroid maturation through differentiation and increased erythroid precursors	EMAs can be used for the treatment of anemia associated with MDS in patients with transfusion-dependent, LR-MDS regardless of previous exposure to ESAs
Erythropoiesis-Stimulating Agents (ESAs)[4-7]	Recombinant human glycoproteins that mimic the effect of EPO, promoting differentiation, proliferation, and survival to drive production of mature RBCs	ESAs are not FDA-approved for treatment of anemia associated with MDS, however there are clinical data to support their use in this setting
Hypomethylating Agents (HMAs)[1,8-11]	Small molecules that are incorporated into nucleic acids, inhibiting DNA methylation and inducing hypomethylation to prevent the silencing of tumor suppressor genes	• HMA use for treatment of LR-MDS is limited to late stages of treatment after failure of 1L ESAs • HMAs are the only FDA-approved therapeutics for patients with HR-MDS who are not suitable for intensive treatment options
Immunomodulatory Agents (IMiDs)[4,12-14]	Modulate E3 ubiquitin ligase substrate specificity, inhibiting proliferation and inducing apoptosis of MDS cells, as well as modulating immune cells in the bone marrow microenvironment to decrease cytopenias	IMiDs are used for the treatment of low- or intermediate-1 risk transfusion-dependent MDS with del(5q) with or without additional cytogenetic abnormalities

The material herein is presented side-by-side for convenience purposes only. Head-to-head comparisons should not be made across products.

Treating Anemia in MDS

A pocket guide on active treatments for anemia due to MDS

Targeted Therapy

	Mechanism of action	Role in MDS
Telomerase Inhibitors[15-17]	Inhibit telomerase activity and prevent the continual growth of malignant cells, promoting cell death	Telomerase inhibitors can be used to treat adult patients with transfusion-dependent, LR-MDS who are unresponsive to or ineligible for ESA use
IDH1/IDH2 Inhibitors[18-22]	Block the activity of mutant IDH1 or IDH2 to induce myeloid differentiation and hematopoietic recovery	IDH1 inhibitors are used for treatment of adult patients with relapsed/refractory MDS and a susceptible *IDH1* (or *IDH2*; under investigation) mutation confirmed by molecular testing

Abbreviations: 1L, first-line; AE, adverse event; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; FDA, United States Food and Drug Administration; HR-MDS, higher-risk MDS; IDH, isocitrate dehydrogenase; IMiD, immunomodulatory drugs; LR-MDS, lower-risk MDS; MDS, myelodysplastic syndromes; RBC, red blood cell; TGF, transforming growth factor.

References: 1. Platzbecker U. *Blood*. 2019;133(10):1096-1107. **2.** Kubasch AS, et al. *Blood Adv.* 2021;5(5):1565-1575. **3.** DailyMed. Luspatercept. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f4d266-3f52-41eb-86ba-0abf3cf468e8 **4.** Trivedi G, et al. *Trends Mol Med*. 2021;27(10):990-999. **5.** Elliot S, et al. *Ann Hematol*. 2014;93:181-192. **6.** DailyMed. Epoetin Alfa. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5 **7.** DailyMed. Darbepoetin Alfa. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9 **8.** Stomper J, et al. *Leukemia*. 2021;35:1873-1859. **9.** DailyMed. Azacitidine. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd9db533-8a49-4d01-99e2-b2db8db1ed38 **10.** DailyMed. Decitabine. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5662c353-05d0-4bd8-87e4-c92ec9ca861e **11.** DailyMed. Cedazurdine and decitabine. Accessed August 2025. https://dailymed. nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be **12.** Lewis R, et al. Cancer Manag Res. 2021;13:645-657.**13.** Roncador M et al. *Blood.* Published online August 4, 2025. doi:10.1182/blood.2025028619. **14.** DailyMed. Lenalidomide. Accessed May 2025. https://dailymed. nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be **15.** Lennox AL et al. Clin Transl Sci. 2024;17(11):e70076. **16.** DailyMed. Imetelstat. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0fab7ca-e578-43c5-9df6-bdaff4182257 **17.** Platzbecker U et al. Lancet. 2024;403(10423):249-260. **18.** Molenaar RJ, Wilmink JW. *J Histochem Cytochem*. 2022;70(1):83-97. **19.** Abou Dalle I, DiNardo CD. *Ther Adv Hematol*. 2018;9(7):163-173. **20.** DailyMed. Ivosidenib. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d **21.** DailyMed. Olutasidenib. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a0c7c8b-b95f-455d-9600-b7351e4397fe **22.** DailyMed. Enasidenib. Accessed May 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.

Bristol Myers Squibb®

spotlight on ANEMIA

Learn more at SpotlightOnAnemia.com